Previous Article | Next Article ![]()
Infection and Immunity, January 2009, p. 399-404, Vol. 77, No. 1
0019-9567/09/$08.00+0 doi:10.1128/IAI.00762-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Institute of Molecular Medicine, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland,1 MRC Laboratory of Molecular Biology, Hills Road, Cambridge, United Kingdom,2 Medical Biochemistry and Immunology, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom,3 Novartis Institute for Biomedical Research, Horsham, West Sussex, United Kingdom4
Received 18 June 2008/ Returned for modification 29 August 2008/ Accepted 28 October 2008
|
|
|---|
|
|
|---|
While the Toll-like receptors represent the most extensively characterized family of pattern recognition receptors, there is an increasing understanding of the role of C-type lectin receptors (CLRs) in innate immune activation by schistosome glycans. One CLR expressed on human dendritic cells (DCs) is DC-specific intracellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN; CD209), which is implicated in the recognition of glycans from various pathogens including schistosomes (6, 33). DC-SIGN has been shown to bind glycans in S. mansoni SEAs, including the LewisX trisaccharide containing carbohydrate lacto-N-fucopentaose III (LNFPIII) and GalNAcb1-4(fuca1-3)GlcNAc (1, 32, 34). In addition, a DC-SIGN homologue, L-SIGN, that is expressed on liver sinusoidal endothelial cells also binds SEA (34) but recognizes different SEA glycans than DC-SIGN (20). In terms of the innate induction of type 2 responses by schistosomes, modulation of DCs to a DC2 phenotype following SEA treatment has been well described (10, 18), with the egg glycan LNFPIII driving the generation of DC2s (30).
In view of the known role for glycans in immune modulation by schistosomes, we investigated the interactions of the mouse CLR SIGNR1 (SIGN-related 1; CD209b). SIGNR1 is one of 7 paralogues of DC-SIGN described in mice in a family which also contains a related pseudogene, SIGNR6 (24, 26). Whether SIGNR1 is expressed on DC subsets is not as yet clear, but it is expressed on spleen marginal zone (MZ), lymph node, and peritoneal macrophages (7, 12, 23, 24, 29). SIGNR1 is known to recognize glycans from different pathogens and has been shown to bind LewisX/Y- and LewisA/B-containing carbohydrates (6, 13). In this study we demonstrate that while SEAs and also schistosome worm antigens are bound by SIGNR1 in vitro, the use of SIGNR1-deficient (–/–) mice (16) reveals that in the absence of the receptor, no alterations in the immunological and pathological response occur following S. mansoni egg injection or during acute and chronic infection.
|
|
|---|
Parasitology and pathology. S. mansoni adult worm antigen (AWA) and SEAs were prepared as described previously (5). AWAs and SEAs were screened for endotoxin contamination, and only antigen batches containing <1 endotoxin unit/mg (Chromogenic LAL, Biowhittaker, MD) were used. Portal perfusion for worm recovery and liver, intestinal, and fecal egg counts were as described previously (4). Parasite fecundity was determined by dividing total tissue (liver and intestine) egg counts by the number of worm pairs present. Livers from mice were taken and fixed in 10% formaldehyde-saline for histology. Sections of liver were stained with hematoxylin and eosin for egg granuloma diameter measurements and Giemsa-stained for eosinophil quantification. Hepatic fibrosis was measured by quantification of collagen by differential staining of histology sections (4). Fibrosis is expressed as micrograms of collagen per milligram of protein. To quantify the extent of liver damage in mice, plasma was recovered for analysis of aspartate aminotransaminase (AST) levels (4).
Cell culture and immunological analysis.
Spleens or mesenteric lymph nodes were removed and passed through 70-µm-pore-size sieves (Falcon) to prepare single-cell suspensions. Cells from liver granulomas were isolated as described previously (37). Splenocytes were depleted of erythrocytes by lysis with ammonium chloride solution. Cells were cultured in RPMI 1640 medium (Biowest, United Kingdom) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (Labtech, United Kingdom), 2 mM L-glutamine (Gibco), 50 U/ml penicillin, and 50 µg/ml streptomycin (Gibco). Cell suspensions were unstimulated (medium) or stimulated with 2.5 ng/ml phorbal 12-myristate 13-acetate (PMA; Sigma, United Kingdom) and 250 ng/ml ionomycin (Sigma, United Kingdom), SEA (20 µg/ml), or AWA (20 µg/ml) at 37°C. Supernatants were harvested after 72 h and stored frozen. Sandwich enzyme-linked immunosorbent assays (ELISAs) were performed to quantify levels of specific cytokines in the supernatants from cell cultures. Reagents for detection of IL-4 were from BD Pharmingen (United Kingdom), and gamma interferon (IFN-
), IL-10, and tumor necrosis factor alpha (TNF-
) reagents were purchased from R&D Systems (United Kingdom). Serum antigen-specific antibody (IgG and IgE) responses to SEA were measured using ELISAs, as described previously (4).
SIGNR1 binding assay. NIH 3T3 fibroblasts stably expressing SIGNR1 were generated as described previously (29) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Paisley, United Kingdom) supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine, and 0.6 mg/ml G418 (Invitrogen). Ligands for SIGNR1 were assessed by competitive binding assays as previously described (29). In brief, NIH 3T3 cells expressing SIGNR1 were plated in 24-well plates the day before experiments. Cells were washed three times with ice-cold medium prior to addition of mannan as an inhibitor for 1 h at 4°C. After pretreatment, fluorescein isothiocyanate (FITC)-labeled zymosan (at a zymosan-to-cell ratio of 20:1) was added for 1 h at 4°C. After incubation, unbound zymosan was removed by four washes with medium, and cells were lysed with 3% Triton X-100. FITC in lysates was quantified using a Titer-Tek Fluoroskan II instrument (Labsystems Group, Basingstoke, United Kingdom) and expressed as relative fluorescence units.
Statistical analysis. All in vivo experiments were performed at least two separate times. The difference between groups was analyzed by a Student's t test. P values of <0.05 were considered significant.
|
|
|---|
![]() View larger version (11K): [in a new window] |
FIG. 1. Testing binding of S. mansoni antigens to SIGNR1 in vitro. SIGNR1-transfected NIH 3T3 cells were preincubated with no inhibitor (–), a known SIGNR1 binding sugar (mannan; 200 µg/ml), S. mansoni SEAs, or AWAs (3, 30, and 300 µg/ml), or rat IgG. FITC-conjugated zymosan was added, and bound FITC was quantified using a fluorimeter (as described in Materials and Methods) and is expressed as relative fluorescence units. Data are representative of two experiments and are expressed as means ± standard error of the means of duplicate samples.
|
), Th2 (IL-4), and regulatory (IL-10) cytokine proteins in the lungs of both groups were no different following primary (Fig. 2B) and secondary (Fig. 2D) egg challenge. These data show that there is no defect in pulmonary response in SIGNR1–/– mice after challenge with Schistosoma eggs.
![]() View larger version (21K): [in a new window] |
FIG. 2. Evaluation of primary and secondary S. mansoni egg pulmonary granulomas in wild-type (WT) and SIGNR1–/– (KO) mice. For study of the primary granulomas, mice were injected intravenously with 5,000 eggs. After 14 days the lungs were removed and fixed for histology sections for measurement of the volume of pulmonary egg granulomas (A), or lungs were isolated and homogenized for ELISA detection of Th1 (IFN- ), Th2 (IL-4), and regulatory (IL-10) cytokine protein, adjusted to nanograms of cytokine per milligram of protein (B). To evoke secondary granulomas, mice were presensitized intraperitoneally with 5,000 eggs and injected 14 days later with 5,000 eggs intravenously. Similar to primary granulomas, 14 days later lungs were removed, and granuloma volume (C) or lung cytokine protein production (D) was evaluated. Data are means ± standard error of the means from 14 to 17 mice per group. A Student's t test was used to test for statistical differences between groups. NS, nonsignificant.
|
There were no statistical differences in the range of parasitological and pathological responses between SIGNR1–/– and wild-type mice following schistosome infection. Worm fecundity and fecal egg excretion were unaltered in deficient mice (Fig. 3A and B), and the size and eosinophil content of granulomas surrounding eggs in the liver were comparable, as were the levels of hepatic fibrosis (Fig. 3C to E). Consistent with normal liver pathology in schistosome infection and intact egg excretion, there were no differences in plasma levels of AST (Fig. 3F), a marker for hepatocyte damage in S. mansoni infection of mice (4). Furthermore, the deficient mice developed the normal downmodulation in inflammatory responses seen in chronic stages of infection, with smaller-sized granulomas in both groups of mice in the chronic stages versus acute stages of infection (Fig. 3C). A characteristic of the hepatic pathology in S. mansoni-infected mice is the upregulation of Arg-1 in the liver, consistent with an increase in alternatively activated macrophages in the liver (9). S. mansoni-infected wild-type and SIGNR1–/– mice had marked elevations in Arg-1 mRNA levels in the livers relative to uninfected mice, with no differences in Arg-1 expression between groups (data not shown). Indeed, IL-4-induced expression of alternatively activated genes Fizz-1, Ym-1, and Arg-1 by peritoneal macrophages was comparable between wild-type and SIGNR1–/– mice (data not shown), indicating no in vivo or in vitro defect in alternative activation of SIGNR1–/– macrophages.
![]() View larger version (31K): [in a new window] |
FIG. 3. Parasitology and pathology following S. mansoni infection of wild-type (WT) and SIGNR1–/– (KO) mice. Mice were infected with 25 cercariae and culled in acute (8 weeks) and chronic (16 weeks) stages of infection. Worm fecundity (eggs per worm pair) (A) and egg excretion (eggs per gram of feces; [epg]) in the feces (B) were determined. The diameter (C) and eosinophil composition (percentage of granuloma cells) (D) of granulomas surrounding eggs in the liver were quantified. Hepatic fibrosis, expressed as micrograms of collagen per milligram liver protein (E), and plasma levels of AST, a marker for hepatocyte damage in S. mansoni infection of mice (F), were analyzed. Data are means ± standard error of the means from 13 to 17 mice per group at 8 weeks and from 9 to 12 mice per group at 16 weeks. A Student's t test was used to test for statistical differences between groups at acute and chronic stages of infection. NS, nonsignificant.
|
, IL-10, and TNF-
were detected by ELISA as these cytokines are implicated in altered immunopathology in schistosome infection of mice (39). Following polyclonal stimulation with PMA/ionomycin, there were no differences in cytokine production between wild-type and SIGNR1–/– mice (Fig. 4). Furthermore, even though SIGNR1 bound SEA and AWA in vitro (Fig. 1), spleen cells from schistosome-infected SIGNR1–/– mice had intact cytokine responses to these antigens upon restimulation (Fig. 4). We also observed no differences in cytokine production by cells from the mesenteric lymph nodes or granuloma (data not shown). In addition, there was no difference in the production of SEA-specific IgG and IgE antibodies between wild-type and schistosome-infected SIGNR1–/– mice (data not shown).
![]() View larger version (19K): [in a new window] |
FIG. 4. Production of cytokines from spleen cells from uninfected and S. mansoni-infected wild-type (WT) and SIGNR1–/– (KO) mice. Spleens were removed, and prepared cell suspensions were cultured in vitro in medium alone, PMA/ionomycin, AWA, or SEA. After 72 h supernatants were assayed by ELISA for IL-4, IFN- , IL-10, and TNF- . Data shown are means ± standard error of the means from 2 to 4 individual spleens and are representative of at least three experiments per time point.
|
|
|
|---|
To investigate the role of SIGNR1 recognition of schistosome antigens in vivo, we used SIGNR1–/– mice (16). We demonstrated that SIGNR1 has no role in a primary or secondary pulmonary granuloma model induced by schistosome eggs, with deficient mice exhibiting an intact capacity to generate an immune response toward egg antigens. Considering that, to date, SIGNR1 expression has been attributed almost exclusively to macrophage populations of the spleen MZ, lymph nodes, and the peritoneum (7, 12, 29), an absence of its expression on alveolar macrophages could have accounted for the lack of an altered immune response in the pulmonary granulomatous model. However, in pulmonary challenge models with S. pneumoniae, SIGNR1 recognizes S. pneumoniae polysaccharides in in vitro assays, and the SIGNR1–/– mice used here have been shown to be more susceptible than wild-type mice to infection (15, 16). In contrast, although SIGNR1 binds Mycobacterium tuberculosis mannosylated lipoarabinomannan (14), infection of SIGNR1–/– mice indicated a limited role for the molecule during infection (38). Indeed, discrepancies between in vitro recognition of pathogen PAMPs by CLRs and the functional role for the CLRs during in vivo infection are features of a number of bacteria (27).
In order to fully elucidate any potential immunological role for SIGNR1 during S. mansoni infection, we infected SIGNR1–/– mice. Analysis of a range of immunological, parasitological, and pathological infection-related parameters demonstrated that SIGNR1–/– mice are comparable to wild-type animals. There was no difference between groups at the acute (8 week) and chronic (16 week) stages of infection, with SIGNR1–/– mice developing the normal downmodulation of granulomatous inflammation that occurred in wild-type mice during chronic stages of infection. Furthermore, while SIGNR1-transfected cells bound SEA and AWA in an in vitro assay, restimulation of spleen, mesenteric, or granuloma cells from schistosome-infected SIGNR1–/– mice with SEA or AWA showed intact production of IFN-
, IL-4, IL-10, and TNF-
. These are cytokines implicated in altered immunopathology in schistosome infection of mice (3, 39). Consistent with no alterations in infection-induced immunity, the levels of SEA-specific IgE and IgG and also anti-AWA (data not shown) in schistosome-infected SIGNR1–/– mice were no different from those of the wild-type group. Alternatively activated macrophages are induced in schistosome infection of mice (9) in part via the egg glycan LNFPIII (2), with alternatively activated macrophages having an essential biological role in infection (8). Consistent with the absence of exacerbated pathology, there were no differences between wild-type and SIGNR1–/– mice in the in vitro or in vivo expression of alternatively activated macrophage markers. Even in heavier, more acute experimental infections (using 100 cercariae), there were also no differences in mortality or inflammatory responses between wild-type and SIGNR1–/– mice (data not shown). These data indicate that in the absence of SIGNR1, mice develop a normal S. mansoni infection.
In a recent in vitro study, multiple CLRs were shown to be involved in the binding and internalization of SEA by DCs, suggesting that DC-SIGN functions in tandem with other CLRs for antigen processing and presentation to occur in response to SEA (35). In our studies the absence of an in vivo effect in SIGNR1–/– mice may be due to the redundancy of this molecule, with other macrophage CLRs, such as other SIGNR molecules, the mannose receptor, or macrophage galactose-type lectin, compensating in recognition of schistosome glycans. Consequently, a number of in vivo studies with mice deficient in CLRs, such as the mannose receptor (17), would undoubtedly prove informative as to which molecules schistosomes target in order to modulate the host toward a type 2 immune response. As shown here with SIGNR1, due to the potential for redundancy and compensatory recognition of glycans, mice with multiple CLR depletions may be required. Ultimately, in the context of the biological function of CLRs in human schistosome infection, studies on the role of DC-SIGN are required. Such studies may be helped by a recent transgenic mouse model designed to express human DC-SIGN. Transgenic mice have been generated that express human DC-SIGN under the control of the CD11c promoter; these revealed a new perspective on the role of DC-SIGN in M. tuberculosis infection (28).
In summary, this study demonstrates that although there was binding of SIGNR1 to immunogenic factors produced in the S. mansoni life cycle, this does not translate to the receptor having in vivo function during S. mansoni infection or egg-induced pulmonary responses. These data illustrate the need for caution when extrapolating from in vitro binding of PAMP in transfected cell assays to biological function during infection.
Published ahead of print on 3 November 2008. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»